NEW YORK, May 27, 2016 /PRNewswire/ --
At present, the Biotech sphere is in a volatile state, but investors playing in this space know that volatility is what makes this industry interesting to consider. Here are this morning's featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), CTI BioPharma Corp. (NASDAQ: CTIC), Lpath Inc. (NASDAQ: LPTN), and Heat Biologics Inc. (NASDAQ: HTBX). Sign up now and gain access to the technical alerts for these stocks at:
Let us now see the performances of these equities after the closing bell on Thursday, May 26, 2016:
Synta Pharmaceuticals Corp.'s stock finished yesterday's trading session at $0.36, which was a correction of 5.11%. A total volume of 319,230 shares was traded. The Company focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. The Company's shares have advanced 56.78% over the previous three months and 3.03% since the start of this year. The stock is trading above its 50-day moving average by 10.21%. Additionally, shares of Synta Pharmaceuticals have a Relative Strength Index (RSI) of 48.50. Sign up and get the alert on SNTA at:
On Thursday, shares in biopharma Company, CTI BioPharma Corp., ended the session at $0.45, which was a slight correction of 0.31% from their previous close. The Company engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the U.S. and internationally. The stock recorded a total volume of 341,690 shares traded. The Company's shares are trading 9.02% below their 50-day moving average. The stock has an RSI of 44.81. The complimentary alert on CTIC can be activated at:
California-based biotechnology Company, Lpath Inc.'s stock saw a correction of 4.06%, closing the session at $0.17 with a total volume of 274,299 shares traded. The Company's shares are trading 16.54% below their 200-day moving average. The stock has an RSI of 43.46. Register for free on ActiveWallSt.com and access the latest strategies on LPTN at:
On Thursday, shares in Heat Biologics Inc. recorded a trading volume of 286,134 shares, and ended the day 5.83% higher at $0.63. The Company focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the U.S. The stock is trading below its 50-day moving average by 4.14%. The Company's shares have an RSI of 55.47. The complete trade setup on HTBX is available for free at:
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
AWS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly at: Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom Email: firstname.lastname@example.org Phone number: 1-858-257-3144
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA